Journal of Molecular Neuroscience

, Volume 23, Issue 3, pp 157–165 | Cite as

APOE genotype effects on alzheimer’s disease onset and epidemiology

  • J. Wesson AshfordEmail author
Original Article


The risk of developing Alzheimer’s disease (AD) is tied most closely to age and appears to follow Gompertzian kinetics. However, specific genetic factors are also linked closely to AD, and the apolipoprotein E (APOE) genotype accounts for as much of 50% of the attributable risk for AD in many populations. This paper reviews the onset, diagnosis, and epidemiology of AD, specifically with regard to the APOE genotype and the interaction of the genotype with age.

Index Entries

Alzheimer’s disease dementia genetics apolipoprotein E Gompertz aging epidemiology 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arendt T. (2001) Disturbance of neuronal plasticity is a critical pathogenetic event in Alzheimer’s disease. Int. J. Dev. Neurosci. 19, 231–245.PubMedCrossRefGoogle Scholar
  2. Ashford J. W., Kindy M. S., Shih W.-J., Cool C., Aleem B., Cobb L., et al. Clinical onset of Alzheimer’s disease (AD) is earlier in patients with an APOE ε4 allele. Annual Meeting, Society for Neuroscience, Orlando, FL, 723.4, 2002.Google Scholar
  3. Ashford J. W. and Jarvik L. (1985) Alzheimer’s disease: does neuron plasticity predispose to axonal neurofibrillary degeneration? N. Engl. J. Med. 313, 388–389.PubMedGoogle Scholar
  4. Ashford J. W. and Mortimer J. A. (2002) Non-familial Alzheimer’s disease is mainly due to genetic factors. J. Alzheimer’s Dis. 4, 169–177.Google Scholar
  5. Ashford J. W., Schmitt F., and Kumar V. (1998a) Diagnosis of Alzheimer’s disease, in Advances in the Diagnosis and Treatment of Alzheimer’s Disease, Kumar, V., and Eisdorfer, C., eds., Springer, New York, pp. 111–151.Google Scholar
  6. Ashford J. W., Mattson M., and Kumar V. (1998b) Neurobiological systems disrupted by Alzheimer’s disease and molecular neurobiological theories of vulnerability, in Advances in the Diagnosis and Treatment of Alzheimer’s Disease, Kumar, V., and Eisdorfer, C., eds., Springer, New York, pp. 53–89.Google Scholar
  7. Ashford J. W., Shan M., Butler S., Rajesekar A., and Schmitt F. (1995) Temporal quantification of Alzheimer’s disease severity: ‘Time Index Model’. Dementia 6, 269–280.PubMedCrossRefGoogle Scholar
  8. Ashford J. W., Shih W.-J., Coupal J., Shetty R., Schneider A., Cool C., et al. (2000) Single SPECT measures of cerebral cortical perfusion reflect “Time-Index” estimation of dementia severity in Alzheimer’s disease. J. Nuclear Med. 41, 57–64.Google Scholar
  9. Blacker D., Haines J. L., Rodes L., Terwedow H., Go R. C. P., Harrell, L. E., et al. (1997) ApoE-4 and age at onset of Alzheimer’s disease: The NIMH genetics initiative. Neurology 48, 139–147.PubMedGoogle Scholar
  10. Blessed G., Tomlinson B. E., Roth M. (1968) The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br. J. Psychiatry 114, 797–811.PubMedCrossRefGoogle Scholar
  11. Breitner J. C. S., Wyse B. W., Anthony J. C., Welsh-Bohmer K., Steffens D. C., Norton M. C., et al. (1999) APOE-ε4 count predicts age when prevalence of AD increases, then declines: The Cache County Study. Neurology 53, 321–331.PubMedGoogle Scholar
  12. Codemo A., Corti M. C., Mazzetto G., Varotto S., Cortella I., Crepaldi G., and Gabelli C. (2000) Education, APOE status and cognitive impairment in the elderly: an epidemiological study in a rural setting. Neurobiol. Aging 21, S246.Google Scholar
  13. Corbo R. M. and Scacchi R. (1999) Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a ‘thrify’ allele? Ann. Hum. Genet. 63, 301–310.PubMedCrossRefGoogle Scholar
  14. Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261, 921–923.PubMedCrossRefGoogle Scholar
  15. Dean C., Leakey M. G, Reid D., Schrenk F., Schwartz G. T., Stringer C., and Walker A. (2001) Growth processes in teeth distinguish modern humans from Homo erectus and earlier hominins. Nature 414, 628–631.PubMedCrossRefGoogle Scholar
  16. Evans D. A., Beckett L. A., Field T. S., Feng L., Albert M. S., Bennett D. A., et al. (1997) Apolipoprotein E ε4 and incidence of Alzheimer disease in a community population of older persons. JAMA 277, 822–824).PubMedCrossRefGoogle Scholar
  17. Farrer L. A., Cupples L. A., Haines J. L., Hyman B., Kukull W. A., Mayeux R., et al. (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: A meta-analysis. JAMA 278, 1349–1356.PubMedCrossRefGoogle Scholar
  18. Folstein M. F., Folstein S. E., and McCugh P. R. (1975) “Mini-Mental State”: A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189–198.PubMedCrossRefGoogle Scholar
  19. Frisoni G. B., Louhiha J., Geroldi C., and Trabucchi M. (2001) Longevity and the epsilon 2 allele of apolipoprotein E: the Finnish Centenarians Study. J. Gerontol. A Biol. Sci. Med. Sci. 56, M75-M78.PubMedGoogle Scholar
  20. Fullerton S. M., Clark A. G., Weiss K. M., Nickerson D. A., Taylor S. L., Stengard J. H., et al. (2000) Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism. Am. J. Hum. Genet. 67, 881–900.PubMedCrossRefGoogle Scholar
  21. Ganguli M., Chandra V., Kamboh I., Johnston J. M., Dodge H. H., Thelma B. K., et al. (2000) Apolipoprotein E polymorphism and Alzheimer’s disease: the Indo-US Cross-National Dementia Study, Arch. Neurol. 57, 824–830.PubMedCrossRefGoogle Scholar
  22. Guo Z., Fratiglioni L., Viitanen M., Lannfelt L., Basun, H., Fastbom J., and Winblad B. (2001) Apolipoprotein E genotypes and the incidence of Alzheimer’s disease among persons aged 75 years and older: variation by use of anti-hypertensive medication? Am. J. Epidemiol. 153, 225–231.PubMedCrossRefGoogle Scholar
  23. Hendrie H. C., Ogunniyi A., Hall K. S., Baiyewu O., Unverzagt F. W., Gureje O., et al. (2001) Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. JAMA 285, 739–747.PubMedCrossRefGoogle Scholar
  24. Hirsch H. R. (1994) Can an improved environment cause maximum lifespan to decrease? Comments of lifespan criteria and longitudinal Gompertzian analysis. Exp. Gerontol. 29, 119–137.PubMedCrossRefGoogle Scholar
  25. Hirsch H. R. (1995) Do intersections of mortality-rate and survival functions have significance? Exp. Gerontol. 30, 147–167.PubMedCrossRefGoogle Scholar
  26. Jarvik G. P., Wijsman E. M., Kukull W. A., Schellenberg G. D., Yu C., and Larson E. B. (1995) Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer’s disease: a case-control study. Neurology 45, 1092–1096.PubMedGoogle Scholar
  27. Jick H., Zornbert G. L., Jick S. S., Seshadri S., and Drachman D. A. (2000) Statins and the risk of dementia. Lancet 356, 1627–1631.PubMedCrossRefGoogle Scholar
  28. Koudinov A. R. and Koudinova N. V. (2001) Essential role for cholesterol in synaptic plasticity and neuronal degeneration. FASEB J. 10, 1858–1869.Google Scholar
  29. Lehmann D. J., Williams J., McBroom J., and Smith A. D. (2001) Using meta-analysis to explain the diversity of results in genetic studies of late-onset Alzheimer’s disease and to identify high-risk subgroups. Neuroscience 108, 541–554.PubMedCrossRefGoogle Scholar
  30. Liu H. C., Hong C. J, Wang S. J., Fuh J. L., Wang P. N., Shyu H. Y., and Teng E. L. (1999) ApoE genotype in relation to AD and cholesterol; a study of 2,326 Chinese adults. Neurology 53, 962–966.PubMedGoogle Scholar
  31. Mauch D. H., Nagler K., Schumacher S., Goritz C., Muller E.-C., Otto A., and Pfrieger F. W. (2001) CNS synaptogenesis promoted by glia-derived cholesterol. Science 294, 1354–1357.PubMedCrossRefGoogle Scholar
  32. Mendiondo M. S., Ashford J. W., Kryscio R. J., Schmitt F. A. (2003) Designing a Brief Alzheimer Screen (BAS). J. Alzheimers Dis. 5, 391–398.PubMedGoogle Scholar
  33. Mesulam M. M. (1999) Neuroplasticity failure in Alzheimer’s disease: bridging the gap between plaques and tangles. Neuron 24, 521–529.PubMedCrossRefGoogle Scholar
  34. Miech R. A., Breitner J. C., Zandi P. P., Khachaturian A. S., Anthony J. C., Mayer L. (2002) Incidence of AD may decline in the early 90s for men, later for women: The Cache County study. Neurology 58, 209–218.PubMedGoogle Scholar
  35. Myers R. H., Schaefer E. J., Wilson P. W. F., D’Agostino R., Ordovas J. M., Espino A., et al. (1996) Apolipoprotein E ε4 association with dementia in a population-based study: the Framingham Study. Neurology 46, 673–677.PubMedGoogle Scholar
  36. Ohm T. G., Scharnagl H., Marz W., and Bohl J. (1999) Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer’s disease-related lesions. Acta Neuropathol. 98, 273–280.PubMedCrossRefGoogle Scholar
  37. Oppenheimer S. (2003) The Real Eve: Modern Man’s Journey Out of Africa. Carroll and Graf Publishers, New York.Google Scholar
  38. Perls T. T., Morris J. N., Ooi W. L., and Lipsitz L. A. (1993) The relationship between age, gender and cognitive performance in the very old: the effect of selective survival. J. Am. Geriatr. Soc. 41, 1193–1201.PubMedGoogle Scholar
  39. Petersen R. C., Smith G. E., Waring S. C., Ivnik R. J., Tangalos E. G., and Kokmen E. (1999) Mild cognitive impairment, clinical characterization and outcome. Arch. Neurol. 56, 303–308.PubMedCrossRefGoogle Scholar
  40. Roses A. D. (1995) Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer’s disease. Ann. Neurol. 38, 6–14.PubMedCrossRefGoogle Scholar
  41. Roses A. D. (1996) Apolipoprotein E: alleles as risk factors in Alzheimer’s disease. Annu. Rev. Med. 47, 387–400.PubMedCrossRefGoogle Scholar
  42. Roses A. D. (1997) Apolipoprotein E: a gene with complex biological interactions in the aging brain. Neurobiol Dis. 4, 170–85.PubMedCrossRefGoogle Scholar
  43. Sacher G. A. (1977) Life table modification and life prolongation, in The Handbook of the Biology of Aging, Finch, C. E., and Hayflick, L., eds., Van Nostrand Reinhold, New York, pp. 582–638.Google Scholar
  44. Saunders A. M., Strittmatter W. J., Schmechel D., St. George-Hyslop P. H., Pericak-Vance M. A., Joo S. H., et al. (1993) Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 43, 1467–1472.PubMedGoogle Scholar
  45. Seshadri S., Drachman D. A., and Lippa C. F. (1995) Apolipoprotein E ε4 allele and the lifetime risk of Alzheimer’s disease: what physicians know, and what they should know. Arch. Neurol. 52, 1074–1079.PubMedGoogle Scholar
  46. Shih W.-J., Ashford J. W., Stipp V., Magoun S. L., Coupal J. J., and Gross K. K. (1999) Consecutive brain SPECT surface three-dimensional displays show progression of cerebral cortical abnormalities in Alzheimer’s disease. Clin. Nuclear Med. 24, 773–777.CrossRefGoogle Scholar
  47. Slooter A. J. C., Cruts M., Kalmijn S., Hofman A., Breteler M. M. B., Van Broeckhoven C., and van Duijn C. M. (1998) Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch. Neurol. 55, 964–968.PubMedCrossRefGoogle Scholar
  48. Strehler B. L. (1977) Time, Cells, and Aging, Academic Press, New York.Google Scholar
  49. Stringer C. (2002) Modern human origins: progress and prospects. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 357, 563–579.PubMedCrossRefGoogle Scholar
  50. Warwick Daw E., Payami H., Nemens E. J., Nochlin D., Bird T. D., Schellenberg G. D., and Wijsman E. M. (2000) The number of trait loci in late-onset Alzheimer disease. Am. J. Hum. Genet. 66, 196–204.CrossRefGoogle Scholar
  51. Winnock M., Letenneur L., Jacqmin-Gadda H., Dallongeville J., Amouyel P., and Dartigues J. F. (2002) Longitudinal analysis of the effect of apolipoprotein E ε4 and education on cognitive performance in elderly subjects: the PAQUID study. J. Neurol. Neurosurg. Psychiatry. 72, 794–797.PubMedCrossRefGoogle Scholar
  52. Wilson P. W. F., Schaefer E. J., Larson M. G., and Ordovas J. M. (1996) Apolipoprotein E alleles and risk of coronary disease. Arterioscler. Thromb. Vasc. Biol. 16, 1250–1255.PubMedGoogle Scholar
  53. Wolozin B., Kellman W., Ruosseau P., Celesia G. G., and Siegal G. (2000) Decreased prevalence of Alzheimer’s disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57, 1439–1443.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc 2004

Authors and Affiliations

  1. 1.Stanford/VA Alzheimer CenterPalo Alto

Personalised recommendations